Loading...

Zynerba Pharmaceuticals

Nasdaq:ZYNE
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZYNE
Nasdaq
$234M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
  • Zynerba Pharmaceuticals has significant price volatility in the past 3 months.
ZYNE Share Price and Events
7 Day Returns
-5%
NasdaqGM:ZYNE
-1.6%
US Pharmaceuticals
-0.9%
US Market
1 Year Returns
43.6%
NasdaqGM:ZYNE
3.3%
US Pharmaceuticals
3.8%
US Market
ZYNE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zynerba Pharmaceuticals (ZYNE) -5% -14.6% 7.5% 43.6% 39.4% -
US Pharmaceuticals -1.6% -4.8% -0.9% 3.3% -0.4% 12%
US Market -0.9% 1.1% 1.1% 3.8% 35.5% 42.1%
1 Year Return vs Industry and Market
  • ZYNE outperformed the Pharmaceuticals industry which returned 3.3% over the past year.
  • ZYNE outperformed the Market in United States of America which returned 3.8% over the past year.
Price Volatility
ZYNE
Industry
5yr Volatility vs Market

ZYNE Value

 Is Zynerba Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Zynerba Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Zynerba Pharmaceuticals.

NasdaqGM:ZYNE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ZYNE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 21%) (0.12%))
0.821
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.821 * 5.96%)
7.62%

Discounted Cash Flow Calculation for NasdaqGM:ZYNE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Zynerba Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:ZYNE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.62%)
2020 -37.60 Analyst x1 -34.94
2021 -37.50 Analyst x1 -32.38
2022 4.80 Analyst x1 3.85
2023 71.90 Analyst x1 53.59
2024 121.70 Est @ 69.26% 84.29
2025 181.70 Est @ 49.3% 116.93
2026 245.89 Est @ 35.33% 147.03
2027 308.71 Est @ 25.55% 171.52
2028 366.45 Est @ 18.7% 189.17
2029 417.43 Est @ 13.91% 200.23
Present value of next 10 years cash flows $899.29
NasdaqGM:ZYNE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $417.43 × (1 + 2.73%) ÷ (7.62% – 2.73%)
$8,763.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,763.68 ÷ (1 + 7.62%)10
$4,203.64
NasdaqGM:ZYNE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $899.29 + $4,203.64
$5,102.93
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,102.93 / 21.06
$242.27
NasdaqGM:ZYNE Discount to Share Price
Calculation Result
Value per share (USD) From above. $242.27
Current discount Discount to share price of $11.10
= -1 x ($11.10 - $242.27) / $242.27
95.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Zynerba Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $11.1 vs Future cash flow value of $242.27
Current Discount Checks
For Zynerba Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Zynerba Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Zynerba Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zynerba Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zynerba Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ZYNE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.19
NasdaqGM:ZYNE Share Price ** NasdaqGM (2019-07-23) in USD $11.1
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.76x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.8x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zynerba Pharmaceuticals.

NasdaqGM:ZYNE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ZYNE Share Price ÷ EPS (both in USD)

= 11.1 ÷ -2.19

-5.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zynerba Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Zynerba Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Zynerba Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:ZYNE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
65.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.99x
United States of America Market PEG Ratio Median Figure of 2,118 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Zynerba Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Zynerba Pharmaceuticals's assets?
Raw Data
NasdaqGM:ZYNE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.23
NasdaqGM:ZYNE Share Price * NasdaqGM (2019-07-23) in USD $11.1
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 186 Publicly-Listed Pharmaceuticals Companies 3.09x
United States of America Market PB Ratio Median Figure of 5,249 Publicly-Listed Companies 1.78x
NasdaqGM:ZYNE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ZYNE Share Price ÷ Book Value per Share (both in USD)

= 11.1 ÷ 3.23

3.44x

* Primary Listing of Zynerba Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zynerba Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Zynerba Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Zynerba Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ZYNE Future Performance

 How is Zynerba Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zynerba Pharmaceuticals expected to grow at an attractive rate?
  • Zynerba Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Zynerba Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Zynerba Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ZYNE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ZYNE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 65.4%
NasdaqGM:ZYNE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 76.2%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ZYNE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ZYNE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 238 74 122 4
2022-12-31 142 6 67 4
2021-12-31 63 -37 -55 4
2020-12-31 0 -37 -47 5
2019-12-31 0 -35 -44 6
NasdaqGM:ZYNE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 0 -32 -37
2018-12-31 0 -32 -40
2018-09-30 -33 -40
2018-06-30 -30 -41
2018-03-31 -29 -37
2017-12-31 -26 -32
2017-09-30 0 -25 -31
2017-06-30 0 -26 -28
2017-03-31 0 -23 -26
2016-12-31 0 -20 -23
2016-09-30 0 -18 -22
2016-06-30 0 -16 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Zynerba Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Zynerba Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ZYNE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Zynerba Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ZYNE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.07 7.83 -0.38 4.00
2022-12-31 2.09 6.14 -1.58 4.00
2021-12-31 -1.98 -1.75 -2.21 2.00
2020-12-31 -1.92 -1.76 -2.14 5.00
2019-12-31 -2.01 -1.84 -2.14 6.00
NasdaqGM:ZYNE Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.19
2018-12-31 -2.61
2018-09-30 -2.82
2018-06-30 -3.05
2018-03-31 -2.79
2017-12-31 -2.48
2017-09-30 -2.57
2017-06-30 -2.60
2017-03-31 -2.67
2016-12-31 -2.58
2016-09-30 -2.48
2016-06-30 -2.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zynerba Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Zynerba Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zynerba Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ZYNE Past Performance

  How has Zynerba Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zynerba Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zynerba Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Zynerba Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Zynerba Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Zynerba Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zynerba Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ZYNE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.09 -36.75 12.98 24.58
2018-12-31 0.09 -39.91 13.24 27.25
2018-09-30 -40.24 12.36 28.20
2018-06-30 -40.74 12.03 29.09
2018-03-31 -37.06 11.23 26.29
2017-12-31 -32.01 10.02 22.81
2017-09-30 0.00 -30.79 9.42 21.88
2017-06-30 0.00 -28.46 8.12 20.63
2017-03-31 0.00 -26.37 6.96 19.71
2016-12-31 0.01 -23.39 6.43 16.78
2016-09-30 0.06 -21.93 6.81 15.19
2016-06-30 0.26 -19.94 7.24 12.96
2016-03-31 0.27 -15.34 6.39 9.16
2015-12-31 0.28 -12.55 5.36 7.45
2015-09-30 0.30 -8.52 3.87 4.95
2015-06-30 0.63 -7.04 4.06 3.61
2015-03-31 0.68 -6.92 4.63 2.97
2014-12-31 0.81 -5.76 4.08 2.40
2014-09-30 0.83 -4.65 3.53 1.80
2013-12-31 0.94 -0.80 0.44 1.13
2012-12-31 0.60 -1.02 0.59 0.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Zynerba Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Zynerba Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Zynerba Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Zynerba Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zynerba Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ZYNE Health

 How is Zynerba Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zynerba Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zynerba Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zynerba Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zynerba Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Zynerba Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zynerba Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:ZYNE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 68.03 0.00 68.30
2018-12-31 57.60 0.00 59.76
2018-09-30 63.79 0.00 66.18
2018-06-30 40.08 0.00 43.12
2018-03-31 50.33 0.00 52.13
2017-12-31 60.95 0.00 62.51
2017-09-30 64.64 0.00 66.25
2017-06-30 71.23 0.00 70.18
2017-03-31 77.76 0.00 77.49
2016-12-31 29.59 0.00 30.97
2016-09-30 30.88 0.00 31.78
2016-06-30 30.77 0.00 32.13
2016-03-31 36.19 0.00 36.81
2015-12-31 39.71 0.00 41.51
2015-09-30 44.38 0.00 44.81
2015-06-30 5.35 0.00 5.74
2015-03-31 6.98 0.00 7.38
2014-12-31 8.47 0.00 9.33
2014-09-30 3.66 0.00 4.36
2013-12-31 -1.20 0.50 0.15
2012-12-31 -0.63 0.50 0.17
  • Zynerba Pharmaceuticals has no debt.
  • Zynerba Pharmaceuticals has no debt compared to 5 years ago when it was 79.1%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Zynerba Pharmaceuticals has sufficient cash runway for 2.1 years based on current free cash flow.
  • Zynerba Pharmaceuticals has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 26% each year.
X
Financial health checks
We assess Zynerba Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zynerba Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ZYNE Dividends

 What is Zynerba Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Zynerba Pharmaceuticals dividends.
If you bought $2,000 of Zynerba Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Zynerba Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Zynerba Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ZYNE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ZYNE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Zynerba Pharmaceuticals has not reported any payouts.
  • Unable to verify if Zynerba Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Zynerba Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Zynerba Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Zynerba Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zynerba Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zynerba Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ZYNE Management

 What is the CEO of Zynerba Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Armando Anido
COMPENSATION $2,001,096
AGE 61
TENURE AS CEO 4.8 years
CEO Bio

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. He has more than 35 years of executive, operational and commercial leadership experience in the biopharmaceutical industry and he launched over 10 prescription medications in several therapeutic areas. He has broad understanding of key issues in the biotechnology industry, including sales and marketing, development and commercialization, strategy and operations and has extensive executive experience in senior leadership and director roles at several biotechnology companies. Prior to joining Zynerba, he served as a Business Consultant to the life science industry from May 2014 to October 2014. He served as the Chief Executive Officer at NuPathe, Inc., from July 25, 2012 to March 2014. He served as the Chief Executive and President of Auxilium Pharmaceuticals Inc. from July 17, 2006 to December 7, 2011. Mr. Anido joined Auxilium in 2006 and grew sales from $42M in 2005, to over $260M in 2011, increasing market capitalization from $200M to over $900M. He served as the Executive Vice President of Sales and Marketing of MedImmune, LLC (alternate name MedImmune Inc.) from February 22, 2005 to January 5, 2006 and its Senior Vice President of Commercial Operations from February 2004 to February 2005 and Senior Vice President of Sales and Marketing since 1999. He served as the Chairman of the Commercial Strategy Team at MedImmune, Inc. and was responsible for the commercial management of its marketed brands. He held several senior marketing positions at GlaxoWellcome, Inc. and its predecessor companies. Prior to MedImmune, Inc. from 1995 to 1999, he served at GlaxoWellcome Inc., where he served as Vice President of Central Nervous System Marketing and also served as its Director of HIV Marketing. Prior to this time, Mr. Anido served in various positions at Lederle Laboratories from 1989 to 1995, including as its Vice President of Anti-Infectives Marketing. He has been a Director at Zynerba Pharmaceuticals, Inc. since 2014. He has been a Non-Executive Director of Auris Medical Holding AG since April 14, 2016. He served as Independent Director of Aviragen Therapeutics, Inc. since September 22, 2015 until February 13, 2018. He is a member of the Board of Directors of Biota Pharmaceuticals, Inc. He served as a Director of Respira Therapeutics, Inc., from May 2012 to September 2014 and Adolor Corporation from August 11, 2003 to December 2011. He served as a Director of NuPathe, Inc., from July 25, 2012 to March 2014. He served as a Director of Auxilium Pharmaceuticals from July 17, 2006 to December 7, 2011. He is a Registered Pharmacist. Mr. Anido holds an MBA in Marketing and Finance and a BS in Pharmacy from West Virginia University.

CEO Compensation
  • Armando's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Armando's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Zynerba Pharmaceuticals management team in years:

3.8
Average Tenure
61
Average Age
  • The tenure for the Zynerba Pharmaceuticals management team is about average.
Management Team

Armando Anido

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
61
TENURE
4.8 yrs

Terri Sebree

TITLE
President
COMPENSATION
$1M
AGE
61
TENURE
4.8 yrs

Jim Fickenscher

TITLE
CFO, VP of Corporate Development & Treasurer
COMPENSATION
$1M
AGE
55
TENURE
2.8 yrs

Will Roberts

TITLE
VP of Investor Relations & Corporate Communications
AGE
50
TENURE
2 yrs

Suzanne Hanlon

TITLE
Secretary
COMPENSATION
$792K
AGE
62
TENURE
4.8 yrs

Liza Squires

TITLE
Chief Medical Officer
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Zynerba Pharmaceuticals board of directors in years:

3.9
Average Tenure
62.5
Average Age
  • The tenure for the Zynerba Pharmaceuticals board of directors is about average.
Board of Directors

Armando Anido

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
61
TENURE
4.8 yrs

Bill Federici

TITLE
Director
COMPENSATION
$167K
AGE
59
TENURE
3.9 yrs

Dan Kisner

TITLE
Director
COMPENSATION
$158K
AGE
72
TENURE
3.9 yrs

Pamela Stephenson

TITLE
Director
AGE
51
TENURE
0.4 yrs

Warren Cooper

TITLE
Lead Independent Director
COMPENSATION
$179K
AGE
66
TENURE
3.7 yrs

Jacqueline French

TITLE
Member of Scientific Advisory Board

John Messenheimer

TITLE
Member of Scientific Advisory Board

Rodney Radtke

TITLE
Member of Scientific Advisory Board

Steven Siegel

TITLE
Member of Scientific Advisory Board

Ken Moch

TITLE
Director
COMPENSATION
$161K
AGE
64
TENURE
3.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
22. Aug 18 Buy John Butler Individual 22. Aug 18 22. Aug 18 5,000 $6.43 $32,153
07. Aug 18 Buy Armando Anido Individual 06. Aug 18 06. Aug 18 15,000 $5.96 $89,423
07. Aug 18 Buy Suzanne Hanlon Individual 06. Aug 18 06. Aug 18 3,800 $5.80 $22,048
07. Aug 18 Buy Terri Sebree Individual 06. Aug 18 06. Aug 18 3,800 $5.79 $22,013
07. Aug 18 Buy James Fickenscher Individual 06. Aug 18 06. Aug 18 8,518 $5.97 $50,842
X
Management checks
We assess Zynerba Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zynerba Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ZYNE News

Simply Wall St News

What Kind Of Investor Owns Most Of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Zynerba Pharmaceuticals is a smaller company with a market capitalization of US$256m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … See our latest analysis for Zynerba Pharmaceuticals NasdaqGM:ZYNE Ownership Summary, July 23rd 2019 What Does The Institutional Ownership Tell Us About Zynerba Pharmaceuticals?

Simply Wall St -

How Much Did Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Pocket Last Year?

See our latest analysis for Zynerba Pharmaceuticals How Does Armando Anido's Compensation Compare With Similar Sized Companies? … We think total compensation is more important but we note that the CEO salary is lower, at US$568k. … However, this does not necessarily mean Zynerba Pharmaceuticals, Inc.

Simply Wall St -

The Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price Is Up 43% And Shareholders Are Holding On

But you can make better returns by buying undervalued shares. … It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at. … There are plenty of other companies that have insiders buying up shares.

Simply Wall St -

Brief Commentary On Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Fundamentals

In the case of ZYNE, it is a company with robust financial health as well as an optimistic growth outlook. … Flawless balance sheet with high growth potential One reason why investors are attracted to ZYNE is its notable earnings growth potential in the near future of 66%. … NasdaqGM:ZYNE Past and Future Earnings, May 16th 2019 Next Steps: For Zynerba Pharmaceuticals, there are three essential factors you should further research: Historical Performance: What has ZYNE's returns been like over the past?

Simply Wall St -

Do Directors Own Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?

Every investor in Zynerba Pharmaceuticals, Inc. … With a market capitalization of US$170m, Zynerba Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Zynerba Pharmaceuticals

Simply Wall St -

Have Insiders Been Buying Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?

So before you buy or sell Zynerba Pharmaceuticals, Inc. … Zynerba Pharmaceuticals Insider Transactions Over The Last Year. … Overall, Zynerba Pharmaceuticals insiders were net buyers last year

Simply Wall St -

Does Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Pay Matter?

Armando Anido has been the CEO of Zynerba Pharmaceuticals, Inc. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Armando Anido's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Do Directors Own Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?

The big shareholder groups in Zynerba Pharmaceuticals, Inc. … With a market capitalization of US$66m, Zynerba Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Zynerba Pharmaceuticals

Simply Wall St -

Should You Take Comfort From Insider Transactions At Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So shareholders might well want to know whether insiders have been buying or selling shares in Zynerba Pharmaceuticals, Inc. … In total, Zynerba Pharmaceuticals insiders bought more than they sold over the last year

Simply Wall St -

When Can We Expect A Profit From Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)?

Zynerba Pharmaceuticals Inc's (NASDAQ:ZYNE):. … With the latest financial year loss of -US$32.0m and a trailing-twelve month of -US$40.2m, the US$95m market-cap amplifies its loss by moving further away from its breakeven target? … I’ve put together a brief outline of industry analyst expectations for ZYNE, its year of breakeven and its implied growth rate

Simply Wall St -

ZYNE Company Info

Description

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Details
Name: Zynerba Pharmaceuticals, Inc.
ZYNE
Exchange: NasdaqGM
Founded: 2007
$233,803,695
21,063,396
Website: http://www.zynerba.com
Address: Zynerba Pharmaceuticals, Inc.
80 West Lancaster Avenue,
Suite 300,
Devon,
Pennsylvania, 19333,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ZYNE Common Stock Nasdaq Global Market US USD 05. Aug 2015
DB 6ZY Common Stock Deutsche Boerse AG DE EUR 05. Aug 2015
LSE 0M40 Common Stock London Stock Exchange GB USD 05. Aug 2015
Number of employees
Current staff
Staff numbers
25
Zynerba Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/24 02:41
End of day share price update: 2019/07/23 00:00
Last estimates confirmation: 2019/06/27
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.